FutureMeds has completed a further funding round underpinned with investment from HGL Private Capital, a UK-based independent boutique investment firm.
Currently operating from 6 sites in Poland, FutureMeds is fast becoming one of Europe’s leading independent Site Management Organizations.
“We are delighted to have HGL Private Capital as partners. The successful funding round and HGL Private Capital’s backing will support further investment across Europe with the FutureMeds Dedicated Research Site Network growing to 12 sites by the end of 2021. We have already found their advice invaluable, and they quickly assimilated our business opportunity and we are confident they will be key partners in helping us to achieve our strategic ambitions.”
– Dr Radoslaw Janiak, CEO of FutureMeds.
HGL’s highly experienced team will continue to provide strategic advice with Ged Gould joining the Board to help turbocharge the growth plans of FutureMeds and help deliver significant shareholder value throughout the journey.
As per FutureMeds’ strategic plan, Dedicated Research Sites will be opening in Bulgaria, the United Kingdom and Ukraine in the coming months.
Ged Gould, Founding Director of HGL Private Capital commented “It is a pleasure to partner with the team at FutureMeds again. The market opportunity is strong for FutureMeds and we look forward to helping the team with their exciting growth plans.”
